

## THEMA-ARTIKEL

### VACCINOLOGIE

#### **Het dilemma van griepvaccinatie bij gezonde kinderen: een afweging tussen directe bescherming en toekomstige onzekerheden**

Elfie Moesker, Shweta Mahajan, Rianne van Gageldonk, Jørgen de Jonge

#### **Referenties**

1. Jin X, Ren J, Li R, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. *MedClinicalMedicine*. 2021;37:100986.
2. Wang X, Li Y, O'Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. *Lancet Glob Heal*. 2020;8(4):e497-510.
3. Annual reporting on surveillance of acute respiratory infections in the Netherlands, winter 2023/2024 – influenza | RIVM. National Institute for Public Health and the Environment. [cited 2025 Jun 30].
4. Mylonakis SC, Mylona EK, Kalligeros M, Shehadeh F, Chan PA, Mylonakis E. How Comorbidities Affect Hospitalization from Influenza in the Pediatric Population. *Int J Environ Res Public Health*. 2022;19(5).
5. Influenza (Seasonal). 2023. Available from: [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)).
6. Bandell A, Kassianos G, Dibben O, El Azzi G. Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019-2023). *Vaccine X*. 2025;25:100666.
7. Boddington NL, Pearson I, Whitaker H, Mangtani P, Pebody RG. Effectiveness of Influenza Vaccination in Preventing Hospitalization Due to Influenza in Children: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2021;73(9):1722-32.
8. Minozzi S, Lytras T, Gianola S, et al. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis. *EClinicalMedicine*. 2022;46:101331.
9. Vaccine Scheduler | ECDC. European Centre for Disease Prevention and Control. 2025. Available from: <https://vaccineschedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=-1>.

10. Flu vaccines for children and young people - GOV.UK. Gov.UK. 2024. Available from: <https://www.gov.uk/government/publications/which-flu-vaccine-should-children-have/flu-vaccines-for-children-and-young-people>.
11. Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. *Vaccines*. 2015;3(2):373.
12. Beyer WEP, Palache AM, De Jong JC, Osterhaus ADME. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: A meta-analysis. *Vaccine*. 2002 Jan 31;20(9-10):1340-53.
13. Christensen SR, Toulmin SA, Griesman T, et al. Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans. *J Virol*. 2019;93(8).
14. Yegorov S, Celeste DB, Gomes KB, et al. Inactivated and live-attenuated seasonal influenza vaccines boost broadly neutralizing antibodies in children. *Cell reports Med*. 2022;3(2).
15. Janssens Y, Joye J, Waerlop G, Clement F, Leroux-Roels G, Leroux-Roels I. The role of cell-mediated immunity against influenza and its implications for vaccine evaluation. *Front Immunol*. 2022;13.
16. Flannery B, Clippard J, Zimmerman RK, et al. Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2015. *Morb Mortal Wkly Rep*. 2015;64(1):10.
17. Abdelwahab EM, Mettenleiter TC. Zoonotic Animal Influenza Virus and Potential Mixing Vessel Hosts. *Viruses*. 2023;15(4).
18. Ahmed R, Old stone MBA, Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. *Nat Immunol*. 2007;8(11):1188-93.
19. Lin T-H, Zhu X, Wang S, et al. A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors. *Science (80- )*. 2024;386(6726):1128-34.
20. WHO. Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003-2015. World Health Organization. 2025.
21. Bodees R, Kreijtz JH, Rimmel Zwaan GF. Yearly influenza vaccinations: a double-edged sword? *Lancet Infect Dis*. 2009;9(12):784-8.
22. Bodees R, Fraaij PLA, Kreitz JHCM, et al. Annual influenza vaccination affects the development of heterosubtypic immunity. *Vaccine*. 2012;30(51):7407-10.
23. Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F. The influenza virus hemagglutinin head evolves faster than the stalk domain. *Sci Reports* 2018 81. 2018;8(1):1-14.
24. Ng S, Nachbaur R, Balmaseda A, et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. *Nat Med*. 2019;25(6):962-7.

25. Zest SJ, Wu NC, Hensley SE, Wilson IA. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. *J Infect Dis.* 2019;219(Suppl\_1):S38–45.
26. Arevalo CP, Le Sage V, Bolton MJ, et al. Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies. *Proc Natl Acad Sci U S A.* 202;117(29):17221-7.
27. Grebe KM, Yudell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? *Microbes Infect.* 2008;10(9):1024-9.
28. Assarsson E, Bui H-H, Sidney J, et al. Immunome analysis of the repertoire of T-cell specificities for influenza A virus in humans. *J Virol.* 2008;82(24):12241-51.
29. Tu W, Mao H, Zheng J, et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. *J Virol.* 2010;84(13):6527-35.
30. Grant EJ, Josephs TM, Loh L, et al. Broad CD8+ T cell cross-recognition of distinct influenza A strains in humans. *Nat Commun.* 2018;9(1):5427.
31. Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. *Nat Med.* 2013;19(10):1305-12.
32. McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. *N Engl J Med.* 1983;309(1):13-7.
33. Wilkinson TM, Li CKF, Chui CSC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nat Med.* 2012;18(2):274-80.
34. Snyder ME, Finlayson MO, Connors TJ, et al. Generation and persistence of human tissue-resident memory T cells in lung transplantation. *Sci Immunol.* 2019;4(33).
35. Hombrink P, Helbig C, Backer RA, et al. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. *Nat Immunol.* 2016;17(12):1467-78.
36. Paterson S, Kar S, Ung SK, et al. Innate-like gene expression of lung-resident memory CD8+ T cells during experimental human influenza. *Am J Respir Crit Care Med.* 2021;204(7):826-41.
37. Wu T, Hu Y, Lee Y-T, et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. *J Leukoc Biol.* 2014;95(2):215-24.
38. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrançois L, Farber DL. Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. *J Immunol.* 2011;187(11):5510-4.
39. Slütter B, Braeckel-Budimir N Van, Abboud G, Varga SM, Salek-Ardakani S, Harty JT. Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity. *Sci Immunol.* 2017;2(7).

40. Connors TJ, Matsumoto R, Verma S, et al. Site-specific development and progressive maturation of human tissue-resident memory T cells over infancy and childhood. *Immunity*. 2023 Aug 8;56(8):1894-1909.e5.
41. Poon MML, Byington E, Meng W, et al. Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. *Cell Rep*. 2021;37(9).
42. Hoft DF, Babusis E, Worku S, et al. Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children. *J Infect Dis*. 2011;204(6):845-53.
43. Universal Influenza Vaccine Technology Landscape | CIDRAP. [cited 2025 Feb 23]. Available from: <https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape>
44. Oftung F, Næss LM, Laake I, Stoloff G, Pleguezuelos O. FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN- $\gamma$  and Granzyme B ELISpot Assay. *Vaccines* 2022. 2022;10(9):1528.
45. Atmar RL, Bernstein DI, Winokur P, et al. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. *Vaccine*. 2023;41(16):2716-22.
46. Evans TG, Bussey L, Eagling-Vose E, et al. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. *Lancet Infect Dis*. 2022;22(6):857-66.
47. van de Ven K, Lanfermeijer J, van Dijken H, et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. *Sci Adv*. 2022;8(50).
48. Swart M, Kuipers H, Milder F, et al. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen. *NPJ Vaccines*. 2023;8(1):1-14.
49. Li J, Wang T, Guo X, et al. Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster with a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus. *J Med Virol*. 2025;97(4):e70326.
50. Andrews SF, Cominsky LY, Shimberg GD, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. *Sci Transl Med*. 2023;15(692).
51. Li Y, Wang X, Zeng X, Ren W, Liao P, Zhu B. Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice. *mLife*. 2023;2(3):308-16.
52. Styles TM, Akhtar A, Gu C, et al. Chimeric hemagglutinin-based universal influenza mRNA vaccine induces protective immunity and bone marrow plasma cells in rhesus macaques. *Cell Reports Med*. 2025;0(0):102369.

53. Nachbagauer R, Feser J, Naficy A, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. *Nat Med.* 2021;27(1):106-14.
54. Zicht houden op luchtweginfecties | RIVM. Rijksinstituut voor Volksgezondheid en Milieu. [cited 2025 Oct 17]. Available from: <https://www.rivm.nl/luchtweginfecties/zicht-houden-op-luchtweginfecties>.
55. SARI-surveillance | RIVM. Rijksinstituut voor Volksgezondheid en Milieu. 2025 [cited 2025 Oct 17]. Available from: <https://www.rivm.nl/luchtweginfecties/sari>
56. Thwaites RS, Uruchurtu ASS, Negri VA, et al. Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine. *Nat Commun.* 2023;14(1).